Safety and Efficacy of Trastuzumab BS
To confirm the safety and efficacy of this drug under the actual use
Gastric Cancer
DRUG: TRASTUZUMAB BS
The incidence of adverse drug reactions in this surveillance, 24 weeks
Assessment of tumor response: Assess the tumor response according to RECIST Ver. 1.1., 24 Weeks
To confirm the safety and efficacy of this drug under the actual use